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Selective analysis of cancer-cell intrinsic
transcriptional traits defines novel clinically
relevant subtypes of colorectal cancer
Claudio Isella1,2, Francesco Brundu3, Sara E. Bellomo1,2, Francesco Galimi1,2, Eugenia Zanella2,
Roberta Porporato2, Consalvo Petti1,2, Alessandro Fiori2, Francesca Orzan1,2, Rebecca Senetta2,4,
Carla Boccaccio1,2, Elisa Ficarra3, Luigi Marchionni5, Livio Trusolino1,2, Enzo Medico1,2,* & Andrea Bertotti1,2,6,*
Stromal content heavily impacts the transcriptional classification of colorectal cancer (CRC),
with clinical and biological implications. Lineage-dependent stromal transcriptional
components could therefore dominate over more subtle expression traits inherent to cancer
cells. Since in patient-derived xenografts (PDXs) stromal cells of the human tumour are
substituted by murine counterparts, here we deploy human-specific expression profiling of
CRC PDXs to assess cancer-cell intrinsic transcriptional features. Through this approach, we
identify five CRC intrinsic subtypes (CRIS) endowed with distinctive molecular, functional and
phenotypic peculiarities: (i) CRIS-A: mucinous, glycolytic, enriched for microsatellite
instability or KRAS mutations; (ii) CRIS-B: TGF-b pathway activity, epithelial–mesenchymal
transition, poor prognosis; (iii) CRIS-C: elevated EGFR signalling, sensitivity to EGFR
inhibitors; (iv) CRIS-D: WNT activation, IGF2 gene overexpression and amplification; and (v)
CRIS-E: Paneth cell-like phenotype, TP53 mutations. CRIS subtypes successfully categorize
independent sets of primary and metastatic CRCs, with limited overlap on existing
transcriptional classes and unprecedented predictive and prognostic performances.
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A
number of classification systems based on gene expression
have been proposed that stratify colorectal cancer (CRC) in
subgroups with distinct molecular and clinical features1–7.
Comparative analyses in different data sets have revealed
substantial classification coherence across the various signatures,
particularly in the case of a ‘Stem/Serrated/Mesenchymal’ (SSM)
subtype endowed with negative prognosis8–10. These classification
efforts have been recently consolidated by a multi-institutional
initiative that comprehensively cross compared the different
subtype assignments on a common set of samples, leading to the
definition of the consensus molecular subtypes11 (CMS).
Interestingly, we and others independently reported that a large
portion of the genes sustaining the SSM subtype (CMS4 within
the CMS) are of stromal origin, and that the presence of stromal
cells, mainly cancer-associated fibroblasts (CAFs), is a strong
indicator of tumour aggressiveness8,9. Paradoxically, this could
suggest that the non-neoplastic populations and the extrinsic
factors of the tumour reactive stroma play the leading role in
dictating cancer progression, while the intrinsic features of
cancer cells convey less relevant cues. Alternatively, in whole
tumour lysates the transcriptional consequences of biologically
meaningful traits that are inherent to cancer cells might be
obscured by the presence of a dominant, lineage-dependent
transcriptional component of stromal origin. Indeed, an
abundant tumour stromal content is expected to mask subtle
gene expression profiles (GEPs) specifically exhibited by cancer
cells. At present, very little is known about how and to what
extent cancer cell-specific gene expression traits contribute to
classify cancer. At least in principle, distilling variants based on
genes that are expressed only by the transformed cells, in
a context that is purified of heterologous multicellular complexity,
might uncover subtypes that demonstrate higher predictive/
prognostic value when used as classifiers.
To tackle this issue, we exploited a large collection (n¼ 515
samples from 244 patients) of patient-derived xenografts
(PDXs)12. In PDXs, the stromal components of the original
tumour are substituted by their murine counterparts as
a consequence of xenotransplantation13,14, so that detection of
their transcripts can be avoided by appropriate use of human-
specific arrays8. On these premises, here we leverage the unique
opportunity afforded by PDXs to selectively explore the cancer
cell-specific transcriptome of colorectal tumours. By doing so, we
define the colorectal cancer intrinsic subtypes (CRIS) and
evaluate their prognostic and predictive potential.
Results
CRC PDXs fail assignment to public transcriptional subtypes.
We and others have recently reported that CRC classification
based on published transcriptional signatures is heavily affected
by the tumour stromal content8,9. As a further evidence to this
notion, we conducted principal component analyses on a large
gene expression data set of primary colorectal tumours
(n¼ 450)15, assembled from information downloaded from the
TCGA data portal (Supplementary Data 1), and confirmed that
stromal genes have a major impact on the transcriptional profiles
of such cases (Supplementary Fig. 1, Supplementary Data 2). To
test whether this scenario extends beyond the context of primary
tumours, we applied three published CRC signatures1–3 to a
proprietary data set (n¼ 185) of CRC liver metastases (CRC-LM)
(GSE73255) using the nearest template prediction (NTP)
algorithm16. This analysis showed that liver metastases behaved
comparably to primary lesions, with a superimposable
classification pattern (Fig. 1a, Supplementary Fig. 2a,b) that was
sustained by similar transcriptional traits (Fig. 1b, Supplementary
Fig. 2c,d). Overall, published signatures confidently classified
a large fraction of metastatic surgical specimens (range 80–95%,
Fig. 1c, Supplementary Data 3).
We then analysed the GEPs of 515 PDXs from CRC-LM from
244 patients (GSE76402)12. To take into account intra-tumour
heterogeneity, for most of the cases (149/244, 61%) multiple
PDXs derived from regionally distinct areas of the original
tumour were profiled (see Methods for details). A total of 115 of
these patients (corresponding to 240 PDX profiles) were
also included in the CRC-LM data set (Supplementary Data 4).
In this setting, confident classification by published signatures
was strongly reduced (range 50–90%; Fig. 1c, Supplementary
Data 5). In particular, we observed a systematic loss of
classification rate in the SSM classes, which had been previously
reported to be mainly sustained by transcripts of stromal
origin8,9 (w2-test assuming as null hypothesis that the fraction
of cases classified as SSM in PDXs is not different from that
obtained in the CRC-LM data set; Po5 10 10, w2¼ 41.084, for
CCS3; Po1 10 4, w2¼ 15.688, for CRCA5; Po5 10 09,
w2¼ 41.679, for CCMS4). SSM classes also demonstrated
the lowest validation rate when comparing the classification of
CRC-LM with that of their corresponding PDXs (Fig. 1d,e,
Supplementary Tables 3 and 5). We reasoned that this discre-
pancy in classification performance between original and
mouse-propagated metastases might be ascribed to obliteration
of human stroma in PDXs and substitution by host mouse
components, which were not detected by human-specific arrays.
In line with previous genetic and phenotypic evidence12,17, the
classification incongruence between PDXs and their original
counterparts is unlikely to be the consequence of genetic or
functional drifts associated with PDX engraftment and
propagation. Indeed, correlative analyses confirmed that the
PDXs and the corresponding original CRC-LMs were
significantly more similar than unmatched PDX/CRC-LM
pairs (Wilcoxon rank sum Po5 10 16, Fig. 1f). Moreover,
in 88% of the cases, the best correlate for each PDX was its
matched original counterpart (Supplementary Data 6). This
suggests that PDXs largely maintain the transcriptional identity of
their pre-implantation surgical pairs and puts forward the
notion that depletion of stroma-derived signals is likely the
major source of transcriptional variation between surgical
specimens and PDXs.
Cancer-cell intrinsic transcriptional traits classify CRC.
The tumour stroma certainly contributes to tumour biology
but at the same time is not a direct expression of the
transformed phenotype of neoplastic cells. Furthermore, classical
histopathological studies have shown that many solid tumours
(including CRC) feature a desmoplastic reaction whereby dense
connective tissue, produced by activated fibroblasts, tends to
prevail quantitatively over areas occupied by cancer cells18,19. We
therefore speculated that stromal content might act as a dominant
source of variation that could mask more subtle—albeit
biologically relevant—traits inherently related to properties of
cancer cells. To explore this hypothesis, we took advantage
from PDX-derived GEPs to uncover cancer-cell intrinsic
transcriptional subtypes in CRC.
By applying non-negative matrix factorization (NMF)20 to the
515-PDX expression data set, we identified optimal partitioning
into five clusters (Fig. 2a, Supplementary Data 7). As previously
described, we employed significance analysis of microarrays
(SAM21; FDRo0.005) and prediction analysis for microarrays
(PAM22; FDR¼ 0.035) to identify 903 genes whose expression
best discriminates each subtype. To generate a cancer-cell
intrinsic classifier that was not influenced by stroma-derived
transcripts in human CRC samples, we excluded from the
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Figure 1 | CRC PDXs fail assignment to public transcriptional subtypes. (a) Heatmap showing NTP classification of the CRC-LM data set based on the
signatures of the CRCA classification system. (b) Submap analysis of CRCA subtype similarity between CRC liver metastases (CRC-LM) and primary
tumours (GSE14333). P values are calculated by Fisher’s exact test using the Submap tool available from Gene Pattern. (c) Column chart showing the
fractions of CRC liver metastases (CRC-LM), or their corresponding PDXs, which were confidently assigned (NTP, FDRo0.2) to the subtypes of three
different public classifiers. (d) Fraction of PDXs assigned to the same class of their corresponding liver metastasis according to the three classifiers
(as in c). (e) Caleydo view of correspondences between the CRCA class assignments of CRC-LM samples and those of their PDX counterparts.
(f) Distribution of Pearson’s correlation values obtained by analysing unmatched (grey line) and matched (red line) CRC-LM/PDX pairs.
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Figure 2 | CRIS classifies both CRC tumours and PDXs based on cancer-cell intrinsic transcriptional traits. (a) NMF-based consensus clustering of the
PDX data set and plot of cophenetic coefficients for K¼ 2–6. (b,c) Heatmap showing NTP-based CRIS classification of the PDX (b) and the CRC-LM
(c) data sets. (d) Column chart showing the fractions of CRC-LMs and PDXs that were confidently classified (FDRo0.2) by CRIS; coloured sub-columns
represent the relative distribution of subtypes within each data set. (e) Column chart showing, for each CRIS subtype, the fractions of samples for which
CRC-LMs and their corresponding PDXs were confidently assigned (FDRo0.2) to the same class. (f) Caleydo view of CRIS correspondences between
CRC-LM samples and their PDX counterparts. (g,h) Heatmaps showing CRIS classification of primary tumours based on RNAseq data from the TCGA
(g) and Affymetrix microarray data of the GSE14333 data set (h). (i) Column chart showing the distribution of CRIS subtypes based on NTP classification
across 16 independent CRC data sets (Supplementary Data 11); NC (non-classified) indicates samples for which NTP could not confidently assign any of the
subtypes (FDR40.2).
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classifier all the transcripts for which 50% or more of the signal
was originated from stromal cells, based on the analysis of
PDX RNAseq data (Methods). By applying this filter, we selected
565 genes with unambiguous epithelial expression (Suppleme-
ntary Data 8). When applied to the PDX training data set
(Fig. 2b), CRIS confidently classified 94% of the samples
(Supplementary Data 7). Importantly, similar classification
results were obtained in the original CRC-LM data set (Fig. 2c,
Supplementary Data 9). All CRIS subtypes maintained a similar
fraction of assigned cases in the PDX and CRC-LM data sets
(Fig. 2d). Submap analysis23 confirmed that each subtype was
associated with similar underlying transcriptional traits in the
PDX and CRC-LM data sets (Supplementary Fig. 3). This
indicates that the transcriptional patterns identified in PDXs are
represented and detectable in their original counterparts, even in
the presence of human stromal cells. This notion is further
reinforced by the high level of concordance observed when
comparing the classification of matched PDXs versus original
tumour pairs (75% and kappa score¼ 0.62 for CRIS versus
28–46% and kappa scores ranging from 0.2 to 0.3 for existing
classifiers) (Fig. 2e,f; compare with Fig. 1d,e).
Because CRIS was derived from metastatic samples grown
as xenografts in mice, we wished to verify whether CRIS
signatures could be also applied to CRC gene expression profiles
obtained in different conditions and by means of diverse
technologies. To this aim, we initially tested the CRIS classifier
against two independent gene expression data sets of primary
CRCs, the previously mentioned 450-sample TCGA RNAseq data
set8,15 (Supplementary Data 1) and GSE14333, a 290-sample
Affymetrix data set24 (Fig. 2g,h, Supplementary Data 10). In both
instances, more than 90% of the samples were significantly
assigned to CRIS classes (Supplementary Data 11). In the case of
the TCGA data set, for which microsatellite instability status was
available, CRIS classification efficiency was high in both
microsatellite-stable (MSS) and microsatellite-unstable (MSI)
samples (93% and 95% of confidently classified samples,
respectively). This was particularly interesting because the CRIS
training data set had very few MSI cases (Supplementary Data 4),
as expected for metastatic CRC25. For additional independent
CRIS validation, we applied the classifier to 14 other data
sets11,26, including one Affymetrix microarray data set of liver
metastases and one Illumina microarray data set of CRC cell lines
(Supplementary Data 11). Overall, CRIS confidently classified
3,396 out of 3,738 samples (90.8%). Further, the five subtypes
maintained a similar fraction of assigned cases, irrespective of
technological platforms and experimental conditions (Fig. 2i).
Submap analysis confirmed that the transcriptional attributes
distinguishing the different subgroups were comparable in
CRC-LM and primary tumours (Supplementary Fig. 4).
Collectively, these results indicate that the transcriptional traits
captured by CRIS reflect stable intrinsic features of cancer cells
and are not ostensibly affected by the origin of the samples or the
expression analysis platform.
Major peculiarities of CRIS classes. Using NTP-calculated
centroid distances in the TCGA data set (Supplementary
Data 11), CRIS classes could be clustered into two major
subfamilies composed of two (CRIS-A and CRIS-B) and three
(CRIS-C, CRIS-D and CRIS-E) members (Fig. 3a; Methods). As
suggested by the asymmetric distribution of mutational and copy
number load (Fig. 3b,c), TCGA MSI and MSS samples
(Supplementary Data 1) were not equally partitioned across CRIS
subfamilies. Specifically, MSI tumours were predominantly
assigned to CRIS-A and—to a lower extent—to CRIS-B (Fisher’s
exact test, CRIS-A/B against all other samples, Po5 10 10,
odds ratio 17.309, confidence interval (CI)¼ 5.670–71.189;
Fig. 3d). These two classes proved to be also enriched for right-
colon tumours featuring mucinous histology, CpG island methy-
lator phenotype (CIMP) and a hypermutator genotype (Fisher’s
exact test, CRIS-A/B against all other samples, Po5 10 3,
odds ratio¼ 2.701, CI¼ 1.459–5.038 for right-colon location;
Po5 10 10, odds ratio¼ 16.207, CI¼ 5.751–56.814 for
mucinous histology; Po1 10 11, odds ratio¼ 27.254,
CI¼ 7.811–147.338 for CIMP; Po5 10 7, odds ratio¼ 16.094,
CI¼ 4.388–89.516 for hypermutator phenotype; Fig. 3d). Of note,
some of these MSI-associated features were also shared by the MSS
members of CRIS-A (‘MSI-like’ samples; Fisher’s exact test, CRIS-
A MSS samples against all other MSS samples, Po5 10 6, odds
ratio¼ 23.231, CI¼ 5.318–144.640 for mucinous histology and
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Figure 3 | Molecular and phenotypic characteristics of CRIS subtypes
in the TCGA data set. (a) Clustering of CRIS classes based on similarity of
the distances, as calculated by NTP, when classifying the TCGA data set.
(b) Frequency of somatic single-nucleotide variations. Individual samples
are represented as black dots; the mean of each CRIS subtype is plotted
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are represented as red or black dots to denote MSI or MSS tumours,
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CRC samples across CRIS subtypes.
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Po5 10 3, odds ratio¼ 10.417, CI¼ 2.031–69.611 for CIMP;
Fig. 3d).
Through an exploratory inspection of broad and focal copy
number changes specifically in MSS samples, we identified
genomic traits peculiar to individual CRIS classes (Fig. 4a,b).
Overall, CRIS-C, D and E typically displayed chromosomal
instability (CIN), characterized by heavy copy number alteration
burden (Wilcoxon rank-sum test, Po5 10 08; Fig. 3c). More
specifically, gains of entire chromosome arms were particularly
evident for CRIS-C (for example, Chr7, Chr8q and Chr20) and
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CRIS-E (Chr13q) (Fig. 4a). Interestingly, CRIS C–D–E
subtypes displayed significant association with specific focal
amplifications (Supplementary Table 1). In particular, besides
some alterations with unknown functional consequences, CRIS-C
displayed focal amplification of 8q.24.21, which contains
the MYC proto-oncogene (Fisher’s exact test, CRIS-C samples
against all other MSS samples, Po0.01, odds ratio¼ 2.802,
CI¼ 1.207–7.006; Fig. 4b). CRIS-D was specifically enriched for
amplification of Chr11p15.5 (Fisher’s exact test, CRIS-D samples
against all other MSS samples, Po1 10 05, odds ratio 6.020,
CI¼ 2.268–17.046; Fig. 4b). This locus contains IGF2, a gene
whose strong overexpression has been reported in a subset of
CRCs15. Accordingly, we observed that Chr11p15.5 amplification
in CRIS-D was paralleled by high IGF2 expression levels (Fig. 4c).
To further investigate the genetic correlates of CRIS transcrip-
tional classes, we took advantage of the mutational profiles
available from the TCGA data portal15. As previously reported27,
the prevalence of mutations in the BRAF gene was high in MSI
samples (Supplementary Data 1). While the few MSS cases with
BRAF alterations did not cluster in any particular CRIS subtype
(Fig. 4d), 13 of the 15 MSI samples with mutated BRAF were
assigned to CRIS-A (one with high FDR) and two to CRIS-B.
Within MSS samples, KRAS was frequently mutated in CRIS-A
(Fig. 4d; Fisher’s exact test, CRIS-A MSS against all other MSS
samples, Po0.005, odds ratio¼ 4.320, CI¼ 1.570–13.274) and,
within the CRIS C–D–E subfamily, specifically in CRIS-E
(Fisher’s exact test, CRIS-E against CRIS-C/D, Po5 10 4,
odds ratio¼ 5.645, CI¼ 2.059–16.120; Fig. 4d). CRIS-C was
instead strongly enriched in KRAS wild-type samples (Fisher’s
exact test, CRIS-C against all other MSS samples, Po1 10 4,
odds ratio¼ 0.161 CI¼ 0.050–0.441; Fig. 4d). Finally, TP53
mutations prevalently occurred in CRIS-E (Fisher’s exact test,
CRIS-E against all other MSS samples, Po0.01, odds
ratio¼ 3.892, CI¼ 1.307–14.156; Fig. 4d), while they were
depleted in CRIS-A and D (Fisher’s exact test, CRIS-A or D
against all other MSS samples, Po0.05 for both, odds
ratio¼ 0.361 with CI¼ 0.132–0.942 for CRIS-A and 0.281 with
CI¼ 0.095–0.771 for CRIS-D; Fig. 4d). By leveraging the genetic
annotations available in our data set of CRC PDXs
(Supplementary Data 4), we were able to confirm several of the
molecular correlates found in the TCGA cohort (Supplementary
Fig. 5). Together, these findings indicate that CRIS subclasses are
endowed with specific genetic traits that presumably drive
functional features associated with the corresponding expression
signatures.
To better delineate the functional attributes inherent to CRIS
subtypes, we exploited both unbiased and supervised approaches.
On the one hand, to gather a comprehensive picture of biological
traits associated with CRIS classes, we ran gene set enrichment
analysis (GSEA) against the ‘Hallmark’ gene sets, a panel of
signatures representing an extensive spectrum of key biological
functions, from the MSigDB (ref. 28) (Fig. 4e, Suppleme-
ntary Data 12). On the other hand, to explore transcriptional
patterns specifically relevant in CRC, we selected ten signatures
capturing different phenotypic or functional aspects of normal
and neoplastic intestinal biology (Supplementary Data 13) and
analysed to what extent each sample displayed the phenotype
captured by every signature. To do this, for each sample and each
signature a transcriptional score was calculated by subtracting the
average expression of the genes negatively associated with the
phenotype from the average expression of the genes positively
associated with the phenotype. Then, to test how the different
CRIS subtypes are enriched for samples strongly displaying the
selected transcriptional signature, we conceived a procedure
named ‘Sample Set Enrichment Analysis’ (SSEA). In SSEA,
samples are ranked by the calculated signature scores, then the
GSEA algorithm is employed to test ‘sample sets’ (in our case
samples belonging to each CRIS subtype) for enrichment in high-
rank samples (Fig. 4e, Supplementary Data 13; see Methods).
Using SSEA, we also estimated the enrichment of each subtype in
mitogenic/anti-apoptotic autocrine loops, as a proxy of growth
factor-dependent oncogenic signalling. In this case, the samples
were ranked based on ‘receptor activity scores’, which were
calculated by averaging the expression of the receptor itself with
that of its ligands (Fig. 4f, Supplementary Data 14; Methods). To
avoid the confounding effect due to dilution of cancer-cell specific
transcripts by stroma-derived RNA, all these analyses were
performed on PDX GEPs.
Both GSEA-based and SSEA-based phenotypic analyses were
concordant in attributing secretory and MSI-like features to
CRIS-A, in agreement with the mucinous histology of this
subgroup detected in the TCGA data set (Fig. 4e). CRIS-A was
also associated with inflammatory traits and a glycolytic/hypoxic
status (Fig. 4e), which is typical of some KRAS-mutated
tumours29 and has been linked to intense secretory activity30,31.
Similar to CRIS-A, CRIS-B featured an inflammatory phenotype
(Fig. 4e); but different from CRIS-A, CRIS-B also displayed
strong TGFb activity and marked traits of epithelial–
mesenchymal transition (EMT) (Fig. 4e). This is consistent with
the established role of TGFb as an EMT inducer32. Interestingly,
blinded pathological inspection of images from the TCGA cancer
digital slide archive33 revealed that CRIS-B members included
a large number of poorly differentiated tumours, in which the
glandular architecture of the original tissue was completely lost or
barely detectable (Supplementary Fig. 6). These preliminary
observations deserve future, more extensive exploration. CRIS-C
was mainly characterized by a combination of elevated ERBB1/3
autocrine stimulation loops and moderate WNT (Fig. 4e,f).
CRIS-D showed traits of high intrinsic IGFR stimulation (in
accordance with the strong prevalence of IGF2 amplification
observed in the TCGA data set) and FGFR activity (Fig. 4f).
Finally, CRIS-D—and, to a lesser extent, CRIS-E—featured high
WNT activity and a bottom crypt phenotype. In particular,
CRIS-D was positive for an LGR5 signature, which typifies
intestinal stem cells34, and CRIS-E displayed a phenotype
recalling WNT-producing Paneth cells (Fig. 4e,f).
In summary, CRIS identified CRC subclasses with different
functional and phenotypic characteristics related to specific
molecular alterations: CRIS-A was an MSI-like, BRAF- or
KRAS-mutated, and secretory subtype with sustained glycolytic
metabolism and inflammatory traits; CRIS-B grouped a subset of
poorly differentiated tumours with active TGFb signalling and
EMT features; CRIS-C clustered KRAS wild-type CIN tumours
exhibiting elevated ERBB/EGFR pathway activity and MYC copy
number gains; CRIS-D tumours were characterized by a typical
stem phenotype with high WNT signalling, associated with strong
enrichment in IGF2 amplification/overexpression and FGFR
autocrine stimulation; CRIS-E again displayed WNT-related
features, but associated with a Paneth-like phenotype and
a TP53-mutated genotype.
Of note, many of these characteristics were not reported to
associate with transcriptional subgroups in previous studies1–7,
strongly suggesting that the elimination of stroma-related effects
during the class discovery process enhanced sensitivity towards
detection of intrinsic cancer cell-specific traits. To further support
this notion, we analysed the distribution of CRIS subtypes across
CMS classes assigned to TCGA samples11. Overall, partition of
the samples by the two classifiers displayed limited overlap
(Fig. 4g; see Supplementary Table 2 for cross-tabulation and
statistics). Most CMS1 samples were assigned to CRIS-A and B;
CMS2 samples were partitioned in CRIS-C, D and E; CMS3
contributed mostly to CRIS-A; and finally, CMS4 was
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orthogonally distributed across all five CRIS classes, with an
enrichment for CRIS-B cases. These differences are largely
attributable to the influence of stromal infiltration, as evidenced
by analysing the distribution of stromal signatures individually
expressed by CAFs, leukocytes or endothelial cells8 (C, L and E
stromal scores, respectively) in the two classifiers. As shown by
the heatmaps in Fig. 4g, asymmetric expression of stromal
signatures (presented as the average expression of the component
genes of each signature) was clearly detected in the CMS partition
but not in the CRIS partition. Indeed, CMS1 samples displayed
a high L score, in line with the fact that BRAF-mutant MSI
CRC tumours, mostly included in CMS1, typically exhibit
an extensive immune cell infiltration11 (Fig. 4g). Conversely,
CRIS-A comprises BRAF-mutant MSI tumours but also
KRAS-mutant MSS samples with MSI-like features, and overall
has distinctive metabolic features. Accordingly, only a fraction of
CRIS-A samples had a high L score, and this class received
additional samples from CMS3, encompassing tumours with
mixed MSI status, enrichment for KRAS mutations, and
metabolic deregulation, but devoid of intense leukocyte
infiltration. Most CMS4 tumours are characterized by very high
levels of all stromal scores, in particular of the C score (Fig. 4g).
The absence of overlaps with CRIS classes corroborates the
notion that assignment to CMS4 mostly depends on stromal
transcript contribution rather than intrinsic cancer-cell features.
A fraction of the CMS1 and CMS4 samples converge into
the CRIS-B group, featuring EMT and high TGF-b signalling;
these pro-invasive traits are indeed assigned by CMS only to
the CSM4 class, probably because they are estimated by stroma-
derived transcripts. A similar lack of overlap with CRIS
classification and asymmetric distribution of stromal scores
across subtypes was also observed when previously published
transcriptional CRC classifiers were applied to the TCGA data
set (Supplementary Fig. 7).
The sensitivity of CRIS for more granular detection of
functionally relevant cancer-cell intrinsic traits is particularly
evident for CMS2. This subgroup, the vastest of the consensus,
includes CIN tumours that show overall upregulation of WNT
targets, and displays consistently low stromal scores. The CMS2
subtype was resolved by CRIS into three distinct groups that
displayed class-specific features superimposed on a common
background of high WNT signalling: CRIS-C is characterized by
high EGFR pathway activity; CRIS-D is enriched for IGF2
overexpressors; CRIS-E contains a high number of samples
with KRAS and TP53 mutations. Collectively, these findings
further attest to the independent value and higher resolution of
CRIS taxonomy.
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Figure 5 | CRIS-C and EGFR pathway activity predict cetuximab
sensitivity. (a) Prevalence of CRIS classes among PDX cases scored as
sensitive or resistant to cetuximab. (b) Bar-of-pie charts showing the
distribution of validated resistance biomarkers (KRAS mutations in codons
12 and 13) and proposed resistance biomarkers (other resistance markers;
for their enumeration, see Supplementary Data 4) in PDXs (pies). The
fraction of sensitive or resistant cases specifically in the PDX subpopulation
that does not harbour resistance biomarkers is shown in the bars. The
analysis encompasses the whole PDX data set, CRIS-C alone, and all other
CRIS classes. (c) Bar-of-pie chart showing the distribution of CRIS subtypes
in KRAS wild-type cases of GSE5851, a data set of CRC liver metastases
annotated for clinical response to cetuximab monotherapy37 (pie). Bars
denote the fraction of tumours responsive or resistant to cetuximab within
CRIS-C or in all other CRIS classes. (d) Average expression of the gene set
indicative of EGFR pathway activity in samples assigned to CRIS-C versus
samples assigned to all other CRIS classes; error bars represent s.d. from
the mean; statistical significance was calculated by Wilcoxon rank-sum test.
(e) Heatmap showing response to cetuximab, average expression of the
gene set indicative of EGFR pathway activity, and expression of individual
genes of the EGFR pathway activity gene set across CRIS classes.
The analysis includes PDXs that do not harbour known genetic markers
of resistance.
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CRIS predicts response to anti-EGFR antibodies. To test whe-
ther CRIS partitioning could predict drug sensitivity, we deployed
expression profiles from 241 PDXs annotated for their response to
the anti-EGFR antibody cetuximab12,35,36 (Supplementary Data 4,
Supplementary Fig. 8). Interestingly, CRIS-C was significantly
over-represented among cetuximab-sensitive tumours and depleted
from resistant cases (Fisher’s exact test, Po5 10 10, odds
ratio¼ 8.23, CI¼ 4.017–17.545; Fig. 5a). The opposite was true
for CRIS-A, which correlated with lack of response (Fisher’s exact
test, Po1 10 5, odds ratio¼ 0.104, CI¼ 0.020–0.354; Fig. 5a).
We and others have identified a number of genetic alterations that
associate with resistance to cetuximab12,36–39. These alterations,
particularly the clinically validated mutations in KRAS and NRAS
genes, were under-represented in CRIS-C (Fisher’s exact test
for KRAS and NRAS, Po1 10 13, odds ratio¼ 0.066,
CI¼ 0.022–0.163; Fig. 5b). In principle, this could suggest that
the higher rate of cetuximab-sensitive CRIS-C tumours is due to
depletion in cases harbouring resistance-conferring alterations.
However, CRIS-C maintained strong predictive power also when
such cases were not factored in the analysis (Fisher’s exact test,
Po1 10 5, odds ratio¼ 3.971, CI¼ 2.08–7.08; Fig. 5b). As an
external validation, we tested CRIS classification on a published
data set of CRC-LM annotated for clinical response to cetuximab40
(GSE5851; Supplementary Data 15). Again, CRIS-C predicted
cetuximab sensitivity both in the whole cohort (Fisher’s exact test,
Po0.005, odds ratio¼ 6.780, CI¼ 1.809–29.62; Supplementary
Fig. 9) and, notably, also when KRAS-mutated samples were
excluded from the analysis (Fisher’s exact test, Po0.05, odds
ratio¼ 6.61, CI¼ 1.07–74.094; Fig. 5c).
Complementary to genetic markers of resistance, the
expression of a set of genes indicative of EGFR pathway activity
has been found to correlate with cetuximab sensitivity35,36,40.
This gene set displayed consistently higher expression in CRIS-C
(Wilcoxon rank-sum test, CRIS-C samples against all other
samples, Po1 10 8; Fig. 5d,e; Supplementary Fig. 10;
Supplementary Tables 4 and 9). Moreover, expression of the
gene set was significantly associated with cetuximab sensitivity
across the whole data set, even after exclusion of all genetic
markers of resistance (Wilcoxon rank-sum test, Po1 10 4;
Supplementary Fig. 11a,b) and—of note—also when CRIS-C
cases were excluded (Wilcoxon rank-sum test, Po5 10 4;
Fig. 5e; Supplementary Fig 11c). Multiple logistic regression
analysis demonstrated that CRIS classes, genetic markers and
EGFR pathway activity transcripts have independent predictive
value (Supplementary Table 3). This suggests that, although
partially overlapping, these layers of information convey
integrative knowledge, which could be combined to obtain
more accurate prediction of cetuximab sensitivity.
CRIS is an independent predictor of CRC prognosis. To
explore CRIS prognostic impact we examined the association
of CRIS subtypes with disease-free survival (DFS) of 290 patients
included in a publicly available and clinically annotated
CRC data set24 (GSE14333; Supplementary Tables 10 and 11).
The analysis revealed a trend towards better prognosis for
CRIS-D tumours and a significant association with worse
prognosis for CRIS-B tumours (log-rank w2, Po5 10 4,
hazard ratio (HR)¼ 2.961, CI¼ 1.615–5.43; Fig. 6a). The
prognostic value of CRIS-B was independent of tumour stage
(Cox regression multivariate analysis, Po5 10 4;
Supplementary Table 4) and was maintained in both Duke’s B
and C patients (Supplementary Fig. 12). This suggests that CRIS-
based stratification could be exploited in combination with
clinical and pathological parameters for a superior prognostic
assessment of CRC. Notably, CRIS-B membership was a negative
predictor of DFS not only in untreated cases (log-rank w2,
Po0.05, HR¼ 2.674, CI¼ 1.045–6.845; Fig. 6b), as previously
reported for high stromal content8,9, but also in cases that
underwent adjuvant treatment (log-rank w2, Po0.005,
HR¼ 3.042, CI¼ 1.366–6.777; Fig. 6c). This indicates that the
negative prognostic value of CRIS-B is not biased by
chemotherapy sensitivity.
To evaluate possible prognostic interactions between the
CRIS-B subtype and high levels of CAF infiltration, we
stratified tumours with high or low CAF content, as previously
estimated in this data set8 (Supplementary Data 10). By this
approach, CRIS-B was found to be informative specifically in
low-CAF tumours (log-rank w2, Po5 10 3, HR¼ 2.707,
CI¼ 1.384–5.295; Fig. 6d and Supplementary Fig. 13a).
Symmetrically, high CAF content predicted poor prognosis only
in non-CRIS-B tumours (log-rank w2, Po5 10 6, HR¼ 5.216,
CI¼ 2.486–10.95; Supplementary Fig. 13b,c). These results
suggest that CRIS-B membership and high CAF infiltration
identify alternative means to acquire analogous traits of cancer
aggressiveness, whose negative prognostic impact is not further
exacerbated by the coexistence of the two (Supplementary
Fig. 14). This observation prompted us to test a prognostic
indicator that integrates CAF score and CRIS-B assignment,
whereby all patients categorized as CRIS-B or high CAF, or
assigned to both groups, were assumed to have a poor prognosis.
The combined classifier performed better than either CAF score
or CRIS-B alone (log-rank w2, Po5 10 5, HR¼ 3.248,
CI¼ 1.843–5.724; Supplementary Fig. 15). As previously
reported8, the contribution of the CAF score was negligible for
treated patients (Supplementary Fig. 16) and, accordingly, the
efficacy of the combined CRIS-CAF predictor was even more
pronounced in untreated cases (log-rank w2, Po5 10 5,
HR¼ 5.736, CI¼ 2.334–14.1; Fig. 6e).
Among those individuals who did not receive adjuvant
treatment based on clinical and pathological parameters, the
integrative deployment of CRIS classes and CAF score was able to
discriminate a relatively large subset (30%) of poor-prognosis
patients who relapsed in 5 years in more than 40% of cases
(sensitivity of 0.68 and specificity of 0.75 for 5-year DFS). The
identification of patients with tumours that, in spite of displaying
‘benign’ clinical and pathological features, appear to have an
aggressive biological behaviour, may prove useful to inform
a more proactive follow up in such high-risk subpopulation.
Importantly, the association between CRIS-B and poor
prognosis was confirmed in an independent cohort of 1,261
samples, which was assembled by combining data from five
independent data sets (Supplementary Fig. 17a; Supplementary
Data 16). Also in this case, both CRIS-B and high CAF content
predicted poor prognosis (Supplementary Fig. 17), but the
combination of CRIS-B and high CAF outperformed either of
the individual indicators (log-rank w2, Po1 10 7, HR¼ 1.777,
CI¼ 1.433–2.204; Fig. 6f).
As an initial attempt to translate the CRIS taxonomy into
a diagnostic tool amenable to clinical applications, we developed
a single-sample classifier based on the top scoring pair algorithm
(TSP)41 and its multiclass extension k-TSP42–44. A TSP is
a binary predictor based on the relative ranking of two
measurements (for example, the expression of a pair of
transcripts), which switch order between two subclasses of
samples. This approach can be extended to multiclass problems
by identifying the TSPs associated with each pair-wise subclass
comparison and then aggregating the votes across all gene pairs.
We took advantage of such method to derive an algorithm for
assignment of CRIS subtypes, which we named CRIS-TSP.
To ensure cross-platform portability of the classifier, candidate
TSP genes were challenged against a training data set of 624 gene
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Figure 6 | CRIS subtypes predict CRC prognosis independent of clinical stage and stromal infiltration. (a) Kaplan–Meier plot of DFS of CRIS subtypes in
GSE14333, a prognostically annotated CRC gene expression data set. (b–e) Kaplan–Meier plot comparing the DFS of CRIS-B patients versus that of all other
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15107
10 NATURE COMMUNICATIONS | 8:15107 | DOI: 10.1038/ncomms15107 | www.nature.com/naturecommunications
expression profiles from both PDXs and original tumours,
obtained using multiple technological platforms (Supplementary
Data 17). This process resulted in the selection of 40 gene
pairs (Methods; Supplementary Data 18). When applied to the
training set, CRIS-TSP demonstrated good concordance with
the original CRIS classifier (K¼ 0.7384). CRIS-TSP was then
applied to eight independent data sets, for a total of 2,024
samples (Supplementary Data 17). When challenged against
six gene expression data sets annotated for clinical outcome
(total samples¼ 1,487), CRIS-TSP assignments confirmed the
poor prognosis of CRIS-B patients (log-rank w2, Po5 10 5,
HR¼ 1.6613, CI¼ 1.307–2.112; Supplementary Fig. 18,
Supplementary Data 17). The classification concordance between
CRIS and CRIS-TSP was, however, suboptimal in these data sets
(K¼ 0.6459). We also found limited concordance when compar-
ing CRIS-TSP classification of surgical resections of liver
metastases versus their corresponding PDXs (K¼ 0.4053), overall
suggesting that the performance of the CRIS-TSP classifier was
less robust when applied outside the training set. To assess
whether such reduced classification coherence was due to
low classification efficacy of the selected TSP genes, we
reconstituted a NTP-based classifier using the same TSP
transcripts (CRIS-NTP80, Supplementary Tables 21 and 22).
When exploiting the CRIS-NTP80 algorithm for classification of
the clinically annotated CRC data sets, the overall classification
concordance with respect to the original full-size CRIS classifier
was improved over CRIS-TSP (K¼ 0.7149). Consistently, the
classification coherence between original tumours and PDXs was
also increased (K¼ 0.5577) and similar to that obtained with the
full-size NTP. CRIS-NTP80 also confirmed the prognostic
significance of CRIS-B (log-rank w2, Po5 10 4, HR¼ 1.581,
CI¼ 1.246–2.006; Supplementary Fig. 18). Altogether, these
data show that reducing the size of the CRIS classifier to
80 genes preserves most of its classifying capability across
different gene expression platforms, and indicate the feasibility
of deploying such a reduced gene set for a single-sample
classification based on a TSP approach.
Discussion
Gene expression analysis based on total RNA of bulk cancer
tissues provides an aggregate portrait of the main components
that make up the whole tumour ecosystem, including cancer cells,
vessels, fibroblasts and immune cells. Although global differences
in gene expression patterns have proved useful to distinguish
cancer subtypes for effective disease stratification45, separating
the molecular signatures of tissue compartments from
measurements of total tumour samples is expected to provide
higher resolution of biologically and clinically pertinent
parameters8,46.
The contribution of individual tumour constituents to better
capturing some cancer characteristics has been mainly documen-
ted for stromal cells in several tumour types. For example,
a signature reflecting response of human fibroblasts to serum,
suggestive of active wounds, was found in a subgroup of cases at
early stages, persisted during treatment, and predicted increased
risk of metastasis and death in breast, lung and gastric
carcinomas47. In pancreatic ductal adenocarcinomas, the
integration of tumour- and stroma-specific gene expression
profiles resulted in improved prognostic power over traditional
signatures46. In CRC, stromal traits have been shown to critically
impact cancer prognosis and response to therapy8,9. On the
contrary, how cancer-cell intrinsic gene expression patterns
influence subtype classification remains elusive, likely because
the proportion of normal tissue lineages present in whole tumour
transcriptomes acts as a dominant source of variation that
obscures biologically relevant transcriptional features inherently
displayed by cancer cells.
To attempt unambiguous exploration of cancer-cell gene
expression attributes we took advantage of a large collection of
PDXs, in which transcripts of manifest cancer-cell origin could be
extracted by the deployment of human-specific probes. The
ensuing transcriptional profiles were then leveraged for a class
discovery effort. This led to the identification of CRIS, an original
classifier that categorizes CRC in five novel transcriptional classes.
Of note, CRIS subclasses only barely overlap with the reported
CRC transcriptional classification systems, which empowers
a higher dimension of analytical resolution and refines biological
insight into CRC heterogeneity. In particular, removal of stromal
signals in the class discovery process resulted in remarkable
orthogonality between CRIS and the recently published
CMS signatures, with lack of classification for CMS subtypes
enriched for mesenchymal phenotypes (CMS1 and CMS4) and
detection of genetic and functional peculiarities with a potential
to instruct novel diagnostic and therapeutic approaches.
CRIS-A is highly enriched for BRAF-mutated MSI tumours
and KRAS-mutated MSS tumours, for which no targeted
treatment options are currently available. It is worth noting
that such tumours typically exhibit strong glycolytic/hypoxic
signatures. Although further studies based on preclinical
experimentation and prospective trials in patients are needed to
support this assumption, CRIS-A might pinpoint tumour
subgroups potentially responsive to anti-metabolic therapies29.
CRIS-B identifies a previously neglected subset of invasive
tumours with poor prognosis and high TGF-b signalling. Since
these characteristics are cancer cell specific, CRIS-B is unrelated
to the CMS4 mesenchymal subtype, which also includes
aggressive tumours and features transcriptional traits of TGF-b
pathway activation, but of stromal origin. Novel therapeutic
approaches targeting TGFb-mediated signals in the stroma have
been recently proposed9; CRIS-B tumours could represent
additional candidates for investigational testing of these drugs.
CRIS-C categorizes tumours that are strictly dependent on EGFR
signals and are sensitive to treatment with anti-EGFR antibodies.
The positive predictive value of CRIS-C is of particular
importance because it proved to be independent of all known
(genetic) biomarkers of response or resistance. CRIS-D groups a
subset of tumours enriched for IGF2 overexpression, which has
been recently implicated in desensitization to EGFR blockade in
patients with KRAS wild-type tumours35. The finding that high
IGF2 levels attenuate dependency on the EGFR pathway
underscores the functional relevance of this alteration, which is
also a candidate target for alternative treatment protocols35.
Finally, CRIS-E aggregates KRAS-mutated, Paneth cell-like CIN
tumours that are refractory to treatment with anti-EGFR
antibodies. High WNT pathway activity was more generally
observed in the CRIS-C–D–E subfamily, thus defining a subset of
tumours for which pharmacologic inhibitors of this pathway48,49
may have therapeutic potential. As a further layer of relevant
information for translational purposes, not only does CRIS
introduce a new partitioning of known molecular traits, but it also
puts forward a number of autocrine signalling loops that are
selectively enriched in distinct classes. If validated through
functional studies, these signals could constitute an entirely
new population of candidate druggable targets for specific
CRC subtypes.
Although the analysis of cancer-cell intrinsic traits can provide
relevant information for CRC management, the contribution
of the stromal compartment should not be overlooked.
We and others have reported that the extent of stromal
infiltration predicts poor outcome, resistance to radiotherapy
and—possibly—sensitivity to chemotherapy8,9. Here we show
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that the capture of cancer-cell intrinsic traits by CRIS can be
efficiently integrated with stromal signatures to obtain
even superior prognostic and predictive power. In particular,
high CAF score and assignment to CRIS-B independently predict
poor prognosis for almost one third of tumours whose clinical
and pathological features would not dictate adjuvant treatment.
Therapeutically, CAF score and CRIS-B can be integratively
employed to stratify CRC patients in three groups: (i) patients
with low CAF, non-CRIS-B tumours have good prognosis
and may be spared adjuvant treatment; (ii) patients with
high CAF-score tumours have poor prognosis but are likely
responsive to adjuvant treatment with standard chemotherapy;
(iii) patients with CRIS-B, low CAF-score tumours have poor
prognosis and are expected to be mostly refractory to
conventional adjuvant regimens, but they might benefit from
investigational therapies with agents targeting the TGF-b
pathway (Fig. 6g). These results call for prospective validation
in larger cohorts for drawing definitive conclusions and, if
confirmed, could have major clinical implications. The translation
of the CRIS taxonomy into a clinically useful companion
diagnostic would require the development of a tool for effective
classification of individual patients. Here we show that a set
of 40 gene pairs amenable to TSP-based single-sample
classification retains the classification power of the original
565 gene classifier. However, the performance of CRIS-TSP was
negatively affected by retrospective application to existing data
sets, likely because of the diversity of procedures adopted and
technological platforms used for data generation. Therefore,
whenever the goal is to classify already available gene expression
data sets obtained by diverse technological platforms
(hybridization-based or sequencing-based), NTP-based CRIS
categorization remains the option of choice. At the same time,
we found that the TSP genes perform well when rechallenged for
classification using the NTP approach. This suggests that
implementation of this signature into a clinically applicable
TSP-based single-sample classifier is feasible for prospective
classification of new samples, for which dedicated and
standardized data-generation procedures can be adopted.
One potential limitation of our study is that some CRIS
features could in fact emerge as a consequence of tumour
xenotransplantation. In principle, the PDX approach might exert
a number of distortive effects on the transcriptome of cancer cells,
including selection drifts related to engraftment and propagation,
limited cross-species reactivity between human and mouse
cytokines with consequent perturbation of paracrine signals,
and lack of proper immune components in recipient animals.
However, the likelihood of a strong impact of such biases on
the CRIS taxonomy is reduced by the observation that
CRIS efficiently classified several data sets from bulk CRC patient
tumours, regardless of their source of origin (primary or
metastatic). A way to conclusively cope with this issue would
be to exploit alternative methods to gather pure cancer cell
transcriptional profiles from patient tumours, and test whether
the key CRIS features remain valid. Such kind of approaches—
mainly based on cell sorting of dissociated tumours or
microdissection of histological specimens—have been already
applied in small-scale efforts50–53, but need to be broadened to
larger data sets for reliable validation54.
In conclusion, our data advocate the integrative exploitation of
independently assessed cancer-cell intrinsic and stromal CRC
transcriptional components as a key opportunity to improve
patients’ management in the context of precision medicine
approaches. Similar findings are beginning to emerge also in other
tumour types, using different methodologies46. This suggests that
the same basic concepts introduced here for CRC can be
generalized, with wide impact on cancer diagnosis and treatment.
Methods
Specimen collection and annotation. A total of 244 tumour samples and
matched normal samples were obtained from patients who had undergone surgical
resection of liver metastases at the Candiolo Cancer Institute, the Mauriziano
Umberto I Hospital and the San Giovanni Battista Hospital (Torino, Italy).
All patients provided informed consent and study approval was obtained from
the review boards of the three institutions (the ‘Comitato Etico Istituto di
Candiolo—FPO IRCCS’, the ‘Comitato Etico Azienda Ospedaliera Mauriziano
Umberto I’ and the ‘Comitato Etico Azienda Ospedaliero-Universitaria Citta` della
Salute e della Scienza’).
PDX generation and annotation. Each collected sample was fragmented and
either frozen or prepared for implantation subcutis as previously described12,55.
Non-obese diabetic/severe combined immunodeficinet mice (4–6 weeks old, both
males and females) were used for tumour implantation. At passage two, multiple
samples were subjected to gene expression profiling: two samples for 225 tumours,
three samples for 13 tumours and four samples for 10 tumours. Whenever possible
(149/244 cases, 61%) the different samples analysed originated from independent
propagation of regionally distinct areas of the same original tumour, with the aim
to take into account intra-tumour heterogeneity. Genetic data and annotation of
sensitivity to cetuximab were obtained as described previously12,36. In vivo
experiments and related biobanking data were stored in the Laboratory Assistant
Suite, a web-based, in-house developed data management system for automated
data tracking56. All animal procedures were approved by the Animal Care
Committee of the Candiolo Cancer Institute, in accordance with Italian legislation
on animal experimentation.
Microarray data generation. RNA was extracted using the miRNeasy Mini Kit
(Qiagen), according to the manufacturer’s protocol. Synthesis of cDNA and
biotinylated cRNA (from 500 ng total RNA) was performed using the
IlluminaTotalPrep RNA Amplification Kit (Ambion), according to the
manufacturer’s protocol. Quality assessment and quantitation of total RNA and
cRNAs were performed with Agilent RNA kits on a Bioanalyzer 2100 (Agilent).
Hybridization of cRNAs (750 ng) was carried out using Illumina Human 48 k gene
chips (Human HT-12 V4 BeadChip). Array washing was performed by Illumina
High Temp Wash Buffer for 10min at 55 C, followed by staining using
streptavidin-Cy3 dyes (Amersham Biosciences). Hybridized arrays were stained
and scanned in a Beadstation 500 (Illumina).
Microarray data preprocessing. For GSE76402, probe intensity data were
extracted using the Illumina Genome Studio software (Genome Studio V2011.1)
and subjected to Loess normalization using the Lumi R package57,58. To minimize
the noise due to cross-species hybridization of transcripts deriving from murine
infiltrates in PDX tissues, two pure murine samples were hybridized on human
arrays8 in a pilot experiment, and all probes that generated detectable signals in this
assay were removed from further analyses. Moreover, following an initial
evaluation of signal quality and distribution, 14 samples were found to be
contaminated by murine or human lymphomas and were not further considered in
the analysis (9967501046_G, 9967501046_H, 6898368007_A, 6898368007_B,
9235792014_K, 9235792014_L, 8981245030_C, 8803828041_C, 9031292068_C,
9031292069_B, 5688887009_I, 8803828041_D, 8981245029_G, 8981245029_H).
For the remaining 515 samples—derived from 244 unique patients—probes
were filtered to select those that showed detectable signal (detection P value¼ 0) in
at least 10% of the samples. For each of such genes, only the probe with the highest
variance of signal was selected. Similar analyses were carried out for the panel of
liver metastatic CRCs composing GSE73255. The panel included a total of 185
samples corresponding to 167 unique patients.
Clinical and molecular annotations from the cancer genome atlas (TCGA).
The TCGA data set was obtained from the TCGA data portal, as described
previously8. Molecular/pathological annotations and IGF2 expression data
were downloaded from the Supplementary Tables of the original work15, while
mutational alteration and DFS data were retrieved from the cBioPortal (TGCA,
Colorectal Adenocarcinoma Provisional data set; http://www.cbioportal.org/
index.do, see Supplementary Tables 1 and 20).
The mutational load was calculated based on exome sequencing (Illumina) data
available from the TCGA data portal. In particular the READ and COAD data sets
were mined. All the somatic mutations were included in the calculation and
normalized assuming an approximate exome size of 30 megabases. The analysis
was carried out with the SomaticSignatures R package59.
To calculate the copy number variation load we took advantage of the segmented
data provided by the Broad Institute and available from the TCGA data portal
(Genome-Wide Human SNP Array 6.0). Only data unambiguously referred to
unique tumour samples were considered. For each sample, all the regions with an
absolute segmented value greater than 0.3 were categorized as altered. This threshold
was chosen based on previous work, in which standard methods for calling a copy
number alteration for a segment in GISTIC analysis of a single sample were
defined60. The copy number load was calculated as the number of nucleotides
included in such altered regions, relative to the sum of all nucleotides in all the
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segments identified in the genome of the patient under consideration. The analysis
was performed using pandas and scipy packages (http://pandas.pydata.org/;
http://docs.scipy.org/doc/scipy/reference/).
To represent gains and losses of whole chromosome arms, we employed the
GISTIC61 results provided by the Broad Institute for the TCGA data set
(broad_values_by_arm.txt).
Focal amplifications were obtained from the GISTIC analysis48 provided by the
Broad Institute in the Firehose portal (http://gdac.broadinstitute.org)
(Supplementary Data 1).
Public metastatic and primary colorectal cancer gene expression profiles.
Affymetrix gene expression profiles of 80 metastatic40 and 290 primary CRCs24
were downloaded from GEO (GSE5851 and GSE14333, respectively). The data set
provided by the Colorectal Cancer Subtyping Consortium, corresponding to
GSE39582, GSE2109, GSE17536, GSE13294, GSE20916, GSE37892, GSE33113,
GSE13067, GSE35896, GSE23878, GSE5851, PETACC3 and KFSYSCC, was
downloaded from the synapse repository. For genes with multiple probe sets, those
with the highest average levels were selected.
Identification of cancer-cell intrinsic transcriptional subclasses. The identifi-
cation of cancer-cell intrinsic subtypes was performed by applying unsupervised
clustering analysis, following consolidated methods1. All the available
transcriptional profiles from PDXs were exploited for class discovery. To take into
account tumour heterogeneity in the process of subtype identification, PDXs
derived from the same original tumour were treated as independent samples. To
maximize the portability of the results across multiple platforms, we restricted our
analyses only to transcripts that were also explored in the RNAseq data set available
from the TCGA data portal. We applied consensus-based NMF20 to the 1,084 most
variable genes. In accordance with Sadanandam et al.1,62, these were selected by
applying a threshold of s.d.¼ 0.8 followed by sample data normalization N (0,1).
NMF was performed with the predetermined number of clusters (K) varying from
2 to 6. Quality of the clustering was evaluated by the cophenetic coefficient, with
K¼ 5 gathering the highest value and K¼ 2, K¼ 3 displaying similarly high
coefficients (Fig. 2a). Among these, K¼ 5 was selected because it (i) demonstrated
higher subtyping resolution, splitting K¼ 2 and K¼ 3 in smaller and more
homogeneous subclusters (Supplementary Fig. 19a) and (ii) maintained, despite the
smaller cluster size, very high cophenetic coefficient also when different s.d.
thresholds were used to select the variable genes (Supplementary Fig. 19b).
Generation of the CRIS classifier. To identify gene signatures able to
discriminate CRIS subtypes, we first focused on the samples that best represented
each subtype, using silhouette width—as previously published1,62—to remove the
samples with negative score values (n¼ 90; Supplementary Fig. 19c) from each
cluster. By applying significance analysis of microarrays21 on the remaining 425
samples, 1,083 genes differentially expressed across subtypes were identified. This
was obtained by applying an FDR threshold of 0.005, which was selected to
maximize the number of genes to be further selected with PAM4, while minimizing
the overall error rate in cross-validation analyses. Through PAM, we then
generated the shrunken centroids of each class by selecting the configuration that
minimized the overall error rate in leave-one-out cross-validation analyses. This led
to further prioritization of the discriminating transcripts to a total of 903 genes,
with an overall error rate of 0.035 (Supplementary Fig. 19d).
For implementation of an NTP-based classifier, we selected genes positively and
specifically associated to each of the subtypes. Indeed, the PAM score represents
the extent and sign of association of each gene to each class. Starting from the
903 genes selected as specified above, 102 genes did not have a positive PAM score
for any of the classes (as a consequence of the centroid shrinkage procedure) and
could not be used for NTP. Then, we deployed our published methodology8 to
remove from the classifier those genes for which the major component of signal
was defined as having stromal origin. To do so, we calculated the fraction of
stromal (mouse) transcripts contributing to the overall signal of each gene using
RNAseq data from CRC PDXs, in which mouse stroma substitutes the human
stroma8. This estimate was exploited to exclude from further analyses 84 genes
characterized by a stromal contribution above 50% (ref. 8), which brought to
717 the number of genes to be processed in subsequent steps. The NTP algorithm
does not allow redundancy between the signatures used to assign membership to
different classes. Thus, all genes featuring a positive PAM score for more than one
class had to be non-redundantly assigned to one class only. To do so, we used our
previously published procedure8 and assigned genes that were positively associated
to more than one class to the best PAM scoring class only when the second highest
value for assignment to another PAM class was at least 0.2 points lower. In all other
cases (corresponding to 152 transcripts), the genes were excluded from the analysis.
This procedure yielded an NTP-compatible classifier composed of 565 genes, with
the following partition: 173 genes for CRIS-A; 73 genes for CRIS-B; 149 genes for
CRIS-C; 86 genes for CRIS-D; 84 genes for CRIS-E (Supplementary Data 8). The
whole analytical pipeline, from class discovery to the 565-gene NTP classifier, is
shown in Supplementary Fig. 20.
Nearest template prediction. NTP-based classification16 was performed using
scripts from the GenePattern Bioportal63 (see URLs). The threshold chosen for
significant classification of a sample was Benjamini–Hochberg-corrected false
discovery rate (BH.FDR)o0.2, as previously reported1. When referring to
published classifications (that is, Fig. 1b, Supplementary Figs 2b,c and 4g),
we employed the class assignments provided in the original works by
Sadanandam et al.1 and Guinney et al.11, respectively.
Development of a simplified single-sample CRIS classifier. To develop a
simplified classification system for CRIS, we used the TSP approach, a rank-based,
parameter-free binary predictor relying on the relative ordering of two features
(for example, the order of expression of two genes), and its extension, the k-TSP
classifier, which aggregates the votes of multiple TSPs and can be used for
multiclass problems41–43,64 as detailed below.
To this end we first identified candidate genes for classifier development
starting from 526 CRIS genes (out of 565) in common across three distinct data
sets obtained from different platforms: 254 PDXs analysed on Illumina
microarrays, 104 RNA-seq samples from TCGA and 266 samples analysed on
Affymetrix microarrays available from the public domain (gse13067, gse13294 and
gse35896), for a total of 624 samples (Supplementary Data 17). We then developed
our ranked-based classifier using the k-TSP algorithm and compared its agreement
with the CRIS classification obtained using the original NTP. None of the 624
samples used to develop our k-TSP-based classifier was included in subsequent
analyses investigating the clinical relevance of the CRIS classification. To
implement our k-TSP classifier we performed the following analytical steps:
(i) identification of the most robust and reproducible set of genes across the three
analytical platforms using integrative correlation (ICOR)65,66; (ii) splitting of the
entire combined data set of 624 samples into training (2/3 of samples) and internal
test (1/3 of samples) sets balanced in terms of platform and CRIS class
composition; (iii) development of the classification rule using the k-TSP algorithm
on the training set; and (iv) assessment of the agreement between k-TSP and NTP
using the internal test set.
The TSP algorithm assigns a sample to a specific phenotype if gene A is larger
than gene B, or to the other phenotype otherwise. Since there are five CRIS classes,
there are ten possible pair-wise comparisons among the CRIS classes: (1) A versus
B; (2) A versus C; (3) A versus D; (4) A versus E; (5) B versus C; (6) B versus D;
(7) B versus E; (8) C versus D; (9) C versus E; and (10) D versus E.
There are 138,075 possible TSPs that can be formed using all combinations of
526 genes. To avoid over-fitting, however, we limited the search space in the
training phase by filtering out all genes that proved to be irreproducible across the
three analytical platforms considered (Illumina, RNA-seq, and Affymetrix). To this
end, we used the MergeMaid R-package to calculate a gene reproducibility index
called ICOR65,66, which allows to identify genes that are reproducible across
distinct data sets without relying on any phenotypic information. We calculated
within each separate study, and for each pair of genes, the correlation coefficient
of expression value ranks across subjects, and then retained only the genes for
which such correlations agreed across studies. Supplementary Figure 21a shows
the histograms, the observed and the null distributions (as obtained from 1,000
permutations) for the three pairwise integrative correlations across the three
data sets. To select the most reproducible genes we analysed the total integrative
correlation obtained by averaging the pairwise integrative correlations using
the expectation-maximization (EM) algorithm67. This approach allowed us to
dichotomize the ICOR values and classify the 526 intrinsic genes based on their
reproducibility across platforms. Supplementary Figure 21b shows the distribution
of the total ICOR along with the thresholds identified by the expectation-
maximization algorithm. In our analyses we retained only the 268 most
reproducible genes with mean ICOR40.488.
There are still 35,778 possible TSPs that can be formed using all combinations
of the 268 most reproducible genes. Hence, to further avoid over-fitting, we
limited the search space in the training phase by selecting only the top 50 most
differentially expressed genes for each class (if available) using a Wilcoxon rank-
sum test, and then by constraining pairing only between genes belonging to the
CRIS classes being considered (that is, searching only pairs between CRIS-A and
CRIS-B genes when training TSPs to distinguish CRIS-A from CRIS-B, and so on).
We then identified k-TSPs for each of the ten pair-wise comparison between the
CRIS classes. To select disjoint TSPs for each class comparison, the genes used to
form pairs were omitted from the search in subsequent comparisons. In selecting
the most discriminative TSPs we started from the comparisons between CRIS-B
and the other classes, since this class showed prognostic value in our previous
analyses. We then proceeded to compare CRIS-C to the other classes, since this
class showed association with EGFR signalling and cetuximab sensitivity in our
previous analyses. We then proceeded with the remaining class comparisons
according to the total number of available genes to form the pairs, in increasing
order. The order of the search was therefore as follows: CRIS-B versus E, versus D,
versus C and versus A; CRIS-C versus E, versus D and versus A; CRIS-E versus D
and versus A; CRIS-D versus A. For each of the ten pair-wise comparisons we
selected from 1 to 5 TSPs, for a total of 10, 20, 30, 40 and 50 disjoint TSPs, using
a total of 20, 40, 60, 80 and 100 non-overlapping genes, respectively.
The classification rule to assign a new sample to a CRIS class was constructed as
follows: (i) classify each sample according to each individual TSP included in the
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k-TSP classifier and available for analysis (that is, discard TSPs for which the
genes were not measured); (ii) count the proportion of votes for each CRIS class
(that is, the number of votes for a specific class divided by the total number of
comparisons involving that class); (iii) assign each sample to the class with the
highest proportion of votes; (iv) in case of ties between three classes or more, do
not classify sample (‘Unassigned’); (v) in case of ties between two classes, assign
samples to the class with the highest proportion of votes in the pair-wise
comparisons between these two classes; do not classify sample otherwise
(‘Unassigned’).
In the training phase on 2/3 of the data, we evaluated the concordance between
the classification obtained using the k-TSP classifier and the reference NTP
classification based on the complete 526 ‘intrinsic’ gene set. We assessed the
agreement starting from the minimum set of ten TSPs (k¼ 1), then incremented
the number of TSPs until reaching the maximum agreement with NTP. Hence, we
developed our kTSP classifier using 10, 20, 30, 40 and 50 non-overlapping TSPs for
a total of 20, 40, 60, 80 and 100 genes, respectively. We then compared the
agreement of the aggregated k-TSP classifier with NTP classification in the training
set and internal testing set and selected the one showing the highest agreement in
the internal testing set (k¼ 4 for each pair-wise comparison, for a total of 40 TSPs
and 80 genes), as shown in Supplementary Table 5. The 80 genes were also used for
NTP-based classification (CRIS-NTP80), by assigning to each CRIS class the
16 TSP genes calling for that class in the pairwise comparisons.
Essential scripts required to apply the CRIS classifiers (NTP and TSP) to
independent tumour data sets are provided with the CRISclassifier R package,
available as a Supplementary Software.
SubMap. The similarity between transcriptional traits underlying subtypes across
different data sets was evaluated using the SubMap R package23 available from gene
pattern (http://www.broadinstitute.org/cancer/software/genepattern/).
Principal component analysis. Principal component analysis (PCA) was
employed to identify the main sources of variation in the TCGA gene expression
data set. In particular, we exploited the PCA class from Scikit-learn python library
(http://scikit-learn.org/stable/). Enrichment analyses were conducted on the first
principal component (PCA0; Supplementary Data 2).
Comparison of CRC-LM and PDX gene expression profiles. Genes with high
variance (0.8) in the PDX data set were used to calculate Pearson’s correlations
for any possible CRC-LM/PDX permutation. Correlations of matched versus
unmatched CRC-LM/PDX pairs were compared by two-tailed Student’s t-test.
Gene set enrichment analyses. The GSEA software was downloaded from the
http://www.broadinstitute.org/gsea/index.jsp. The significance of enrichment was
estimated using default settings and 1,000 gene permutations28,68.
Sample set enrichment analysis. For SSEA of curated functional signatures,
a score was calculated for each signature and each sample using median-centered
Log2 ratios of gene expression values, as follows:
Signature scorej ¼ ModuleUPj ModuleDOWNj;
where ModuleUP is the average expression value of the genes positively correlated
with the phenotype and ModuleDOWN is the average expression value of the
transcripts anti-correlated with the phenotype in sample j.
We then evaluated the enrichment in class assignment for each CRIS class by
performing GSEA preranked analysis using as ranked lists the samples ordered by
the score of interest, and as sets the lists of sample membership to the different
CRIS subtypes. Calculations were done with 1,000 permutations.
For SSEA of autocrine loops, a total of 472 receptor/ligand interactions
were downloaded from the Database of Ligand Receptor Partners (http://dip.doe-
mbi.ucla.edu/dip/DLRP.cgi). Then, each set of genes encoding the receptor and its
ligands was used to rank samples, based on median-centered Log2 ratios of gene
expression values, as follows:
Receptor Activation Scorej ¼
Receptorjþ Ligandsj
2
;
where Receptor is the mRNA expression of the receptor of interest and Ligands
stands for the average expression of its corresponding ligands in sample j.
Statistical analyses. Statistical analyses were performed by two-tailed Student’s
t-test, Wilcoxon rank test, Fisher’s exact test and w2-test using the GraphPad Prism
software or statistical R packages. For survival analyses, Cox regression hazard
model and Kaplan–Meier analyses were conducted using the R-Bioconductor
‘survival’ package7,22. For all tests, the level of statistical significance was set at
Po0.05. In case of multiple testing, the results were considered significant when
the Benjamini–Hochberg FDR was below 0.2.
Code availability. Essential scripts to reproduce our classification on
independent CRC data sets can be found in R package CRISclassifier, provided
as Supplementary Software to the manuscript. The CRISclassifier package
was designed to provide easy and guided access to the full CRIS classification
criteria and the TSP-based implementation. Updated versions of this package
will be available on Bioconductor (package name: CRISclassifier). Contact
claudio.isella@ircc.it for more information.
Data availability. Gene expression microarray data generated in the course of this
study have been deposited in the GEO database with accession number GSE76402
(PDX data, 529 profiles from 244 patients) and GSE73255 (liver metastases data,
185 profiles from 167 patients).
Other gene-expression data that support the findings of this study are available
through the TCGA data portal (TCGAcrcmRNA; URL http://bioconductor.org/
packages/release/data/experiment/html/TCGAcrcmRNA.html); from the GEO
database (GSE5851, GSE14333; URL https://www.ncbi.nlm.nih.gov/geo/) and from
the Synapse data portal from the Colorectal Cancer Molecular Subtyping
Consortium (GSE39582, GSE2109, GSE17536, GSE13294, GSE20916, GSE37892,
GSE33113, GSE13067, GSE35896, GSE23878, GSE5851, PETACC3 and KFSYSCC;
URL http://sagebase.org/research-projects/colorectal-cancer-subtyping-
consortium-crcsc/).
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